Intellia Therapeutics Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $37.11
- Today's High:
- $38.68
- Open Price:
- $38.25
- 52W Low:
- $32.435
- 52W High:
- $69.28
- Prev. Close:
- $38.25
- Volume:
- 681345
Company Statistics
- Market Cap.:
- $3.38 billion
- Book Value:
- 12.506
- Revenue TTM:
- $53.04 million
- Operating Margin TTM:
- -867.12%
- Gross Profit TTM:
- $-367858000
- Profit Margin:
- 0%
- Return on Assets TTM:
- -23.62%
- Return on Equity TTM:
- -45.68%
Company Profile
Intellia Therapeutics Inc had its IPO on 2016-05-06 under the ticker symbol NTLA.
The company operates in the Healthcare sector and Biotechnology industry. Intellia Therapeutics Inc has a staff strength of 598 employees.
Stock update
Shares of Intellia Therapeutics Inc opened at $38.25 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $37.11 - $38.68, and closed at $37.15.
This is a -2.88% slip from the previous day's closing price.
A total volume of 681,345 shares were traded at the close of the day’s session.
In the last one week, shares of Intellia Therapeutics Inc have slipped by -1.43%.
Intellia Therapeutics Inc's Key Ratios
Intellia Therapeutics Inc has a market cap of $3.38 billion, indicating a price to book ratio of 4.0088 and a price to sales ratio of 59.6617.
In the last 12-months Intellia Therapeutics Inc’s revenue was $53.04 million with a gross profit of $-367858000 and an EBITDA of $-451708000. The EBITDA ratio measures Intellia Therapeutics Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Intellia Therapeutics Inc’s operating margin was -867.12% while its return on assets stood at -23.62% with a return of equity of -45.68%.
In Q2, Intellia Therapeutics Inc’s quarterly earnings growth was a positive 0% while revenue growth was a negative 3.1%.
Intellia Therapeutics Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
- 0
Its diluted EPS in the last 12-months stands at $-5.4 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Intellia Therapeutics Inc’s profitability.
Intellia Therapeutics Inc stock is trading at a EV to sales ratio of 50.1253 and a EV to EBITDA ratio of -6.119. Its price to sales ratio in the trailing 12-months stood at 59.6617.
Intellia Therapeutics Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $1.32 billion
- Total Liabilities
- $99.85 million
- Operating Cash Flow
- $0
- Capital Expenditure
- $4.30 million
- Dividend Payout Ratio
- 0%
Intellia Therapeutics Inc ended 2024 with $1.32 billion in total assets and $0 in total liabilities. Its intangible assets were valued at $1.32 billion while shareholder equity stood at $1.10 billion.
Intellia Therapeutics Inc ended 2024 with $0 in deferred long-term liabilities, $99.85 million in other current liabilities, 9000.00 in common stock, $-1403994000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $171.81 million and cash and short-term investments were $1.07 billion. The company’s total short-term debt was $16,750,000 while long-term debt stood at $0.
Intellia Therapeutics Inc’s total current assets stands at $939.62 million while long-term investments were $226.88 million and short-term investments were $736.27 million. Its net receivables were $5.06 million compared to accounts payable of $11.63 million and inventory worth $-164013000.00.
In 2024, Intellia Therapeutics Inc's operating cash flow was $0 while its capital expenditure stood at $4.30 million.
Comparatively, Intellia Therapeutics Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $37.15
- 52-Week High
- $69.28
- 52-Week Low
- $32.435
- Analyst Target Price
- $83.75
Intellia Therapeutics Inc stock is currently trading at $37.15 per share. It touched a 52-week high of $69.28 and a 52-week low of $69.28. Analysts tracking the stock have a 12-month average target price of $83.75.
Its 50-day moving average was $40.15 and 200-day moving average was $39.98 The short ratio stood at 9.38 indicating a short percent outstanding of 0%.
Around 534.3% of the company’s stock are held by insiders while 8789.8% are held by institutions.
Frequently Asked Questions About Intellia Therapeutics Inc
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of curative therapeutics. The company’s in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as for other product candidates, including NTLA-2003 for alpha-1 antitrypsin deficiency-liver disease; and NTLA-3001 for alpha-1 antitrypsin deficiency-lung disease; and NTLA-6001 for CD30+ lymphomas. It also focus on programs comprising hemophilia A and hemophilia B; ex vivo pipeline including NTLA-5001 for the treatment of acute myeloid leukemia; and proprietary programs focused on developing engineered cell therapies to treat various cancers and autoimmune diseases. In addition, it offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. Further, the company has license and collaboration agreement with Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; and AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies, and co-develop and co-commercialize allogeneic universal CAR-T cell products for an immuno-oncology indication; and SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases. Additionally, it has license and coloration agreement with Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of a variety of B cell-mediated autoimmune diseases; ONK Therapeutics, Ltd. to develop optimally engineered natural killer cell therapies to cure patients with cancer; and Novartis Institutes for BioMedical Research, Inc. to engineer hematopoietic stem cells for the treatment of sickle cell disease. The company was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.